Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.49 |
| ▸ | SGK1 | O00141 | 1/20 | 0.49 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KDM6B | O15054 | 1/20 | 0.47 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.47 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29245472 | 0.89 | PIK3CA (0.51) | ALOX15HTTPIK3CANEK1MEN1 | |
| SCHEMBL9907326 | 0.84 | PIK3CA (0.57) | PIK3CACAMKK2MEN1KMT2AKDM4E | |
| SCHEMBL9907404 | 0.84 | ALOX15 (0.52) | ALOX15HTTMEN1KMT2ATGFBR1 | |
| SCHEMBL9909216 | 0.84 | EGLN2 (0.47) | ALOX15HTTTGFBR1KDM4EKDM6B | |
| SCHEMBL9907398 | 0.84 | ALOX15 (0.46) | ALOX15HTTPIK3CAEGFRSGK1 | |
| SCHEMBL9909202 | 0.83 | HTT (0.51) | ALOX15HTTCAMKK2TGFBR1KDM4E | |
| SCHEMBL15500539 | 0.82 | PIK3CA (0.55) | PIK3CACAMKK2MEN1KMT2ATGFBR1 | |
| SCHEMBL16549247 | 0.82 | MAPT (0.50) | ALOX15HTTPIK3CAEGFRSGK1 | |
| SCHEMBL9909187 | 0.81 | HTT (0.46) | ALOX15HTTTGFBR1KDM4EKDM6B | |
| SCHEMBL16549268 | 0.81 | AXL (0.47) | ALOX15HTTNEK1TGFBR1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-112105354-A | Fibroblast activation protein inhibitor | 普拉西斯生物技术有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2463276-B1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-2463276-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2011016504-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | ALOX15 3025/4885HTT 3896/4885PIK3CA 502/4885 |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | ALOX15 1101/4885HTT 970/4885PIK3CA 3492/4885 |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | ALOX15 3025/4885HTT 3896/4885PIK3CA 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.